Residual disease in chronic myeloid leukemia after induction of molecular remission.

被引：12

作者：

Lange, T ^{[1
]}

Niederwieser, DW ^{[1
]}

Deininger, MWN ^{[1
]}

机构：

[1] Univ Leipzig, D-04103 Leipzig, Germany

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2003年 / 349卷 / 15期

关键词：

D O I：

10.1056/NEJM200310093491521

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1483 / 1484

页数：2

相关论文

共 5 条

[1] Complete molecular remission in chronic myelogenous leukemia after imatinib therapy
Barbany, G
Höglund, M
Simonsson, B
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 539 - 540
[2] The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
Bose, S
Deininger, M
Gora-Tybor, J
Goldman, JM
Melo, JV
[J]. BLOOD, 1998, 92 (09) : 3362 - 3367
[3] CROSS NCP, 1993, BLOOD, V82, P1929
[4] Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients
Guo, JQ
Lin, H
Kantarjian, H
Talpaz, M
Champlin, R
Andreeff, M
Glassman, A
Arlinghaus, RB
[J]. LEUKEMIA, 2002, 16 (12) : 2447 - 2453
[5] Hughes T, 2002, BLOOD, V100, p93A